VIATRIS INC. Supplier Finance Program Obligation Increase
VIATRIS INC. (VTRS) reported Supplier Finance Program Obligation Increase of $162.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Payables and Accruals
us-gaap:SupplierFinanceProgramObligationIncrease · last filed 2026-02-26
- VIATRIS INC. supplier finance program obligation increase for fiscal 2025 was $162.60M, a 3.24% increase from fiscal 2024.
- VIATRIS INC. supplier finance program obligation increase for fiscal 2024 was $157.50M.
| Period end | Supplier Finance Program Obligation Increase 12 month |
|---|---|
| 2025-12-31 | $162.60M 10-K · filed 2026-02-26 |
| 2024-12-31 | $157.50M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |